Last reviewed 2026-04-22 · How we verify

CYC

CYC is a cyclophosphamide-based chemotherapy agent that alkylates DNA to inhibit cancer cell proliferation.

CYC is a cyclophosphamide-based chemotherapy agent that alkylates DNA to inhibit cancer cell proliferation. Used for Sarcoma (various histologies), Soft tissue sarcoma, Bone sarcoma.

At a glance

Mechanism of action

Cyclophosphamide is a nitrogen mustard alkylating agent that forms covalent bonds with DNA, causing cross-linking and strand breaks that prevent cell division. It is a prodrug requiring hepatic activation and is used primarily in sarcoma and other malignancies. The drug is non-cell-cycle specific and has immunomodulatory effects in addition to direct cytotoxic activity.

Approved indications

• Sarcoma (various histologies)
• Soft tissue sarcoma
• Bone sarcoma

Common side effects

• Myelosuppression
• Nausea and vomiting
• Alopecia
• Hemorrhagic cystitis
• Infertility
• Secondary malignancy

Key clinical trials

• Gonadotropin-releasing Hormone Agonist (GnRHa) in Ovarian Preservation in SLE Subjects Receiving Cyclophosphamide as Determined by Questionnaires
• Upfront Autologous HSCT Versus Immunosuppression in Early Diffuse Cutaneous Systemic Sclerosis (PHASE4)
• Cyclophosphamide in the Treatment of Associated Acquired Lipodystrophy Syndrome With Type 1 Diabetes (NA)
• Ultrastructural Characteristics of Mitochondria in Cardiomyocytes in Heart Failure
• Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM (PHASE1)
• A Study With Imlifidase in Anti-GBM Disease (PHASE3)
• CARTIMMUNE: Study of Patients With Autoimmune Diseases Receiving KYV-101 (PHASE1)
• Effects of Telitacicept vs Cyclophosphamide on Lupus Related Interstitial Lung Disease (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.